CAP@YourService – January/Febuary
Representatives from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) held a joint meeting to launch the development of detailed guidelines for the evaluation of key biomarkers by FISH and mutation testing for use in treatment selection in the clinical management of lung cancer.
The two-day, invitation-only session took place in Chicago in mid-December and attracted delegates representing the three organizations, as well as other clinical and professional organizations, government, and private industry. The gathering marked the first time these national and international associations of clinicians involved in lung cancer diagnosis and care have met to collaborate on the development of evidence-based guidelines.
“This marks a significant development in the continuum of care from diagnosis through treatment,” said John Olsen, MD, scientific and medical director for the CAP Pathology and Laboratory Quality Center. “Patients benefit when clinicians collaborate. This meeting was a chance for physician specialists to gather together to listen, respond, debate, and consider current literature. Then, they will collaboratively draft recommendations that we expect will set the bar for care in the United States and around the world.”
After a public comment period in 2011, the final guidelines will appear in the Archives of Pathology and Laboratory Medicine, the Journal of Thoracic Oncology, and the Journal of Molecular Diagnostics.